

April 12, 2022
REGISTRATION OPEN
THIS WILL BE A VIRTUAL CONFERENCE
TOPIC: Subgroup Analysis in Clinical Trials:
Opportunities and Challenges

MORNING SESSION
David Kent, MD (Tufts University) <i>Overview: Overall average treatment effects and one-variable-at-a-time subgroup analysis: The Scylla and Charybdis of Evidence Based Medicine</i>
Ellis Unger, MD (Consultant) <i>An "unofficial" US Regulatory Perspective</i>
Tom Fleming, PhD (University of Washington) <i>Pitfalls of subgroup analysis</i>
Lisa McShane, PhD (NCI) <i>Finding the subgroup of patients who benefit from a novel therapy: no time for a game of hide and seek</i>
AFTERNOON SESSION
Noah Simon, PhD (University of Washington) <i>Adaptive Enrichment Trials: Identifying the 'right' subgroup</i>
Anastasia Ivanova, PhD (UNC) <i>Methodological challenges in PreClSE (Precision Interventions for SEvere asthma)</i>
Ilya Lipkovich, PhD (Eli Lilly) <i>Comparison of recent approaches for subgroup identification from clinical and observational data</i>
Patrick Schnell, PhD (Ohio State) <i>Multiplicity considerations for analyses of non-exchangeable subgroups</i>
PANELISTS
Mark Rothmann (FDA) Kosuke Imai (Harvard) Kit Roes (European Regulatory Perspective) Michael Rosenblum (Johns Hopkins) Janet Wittes (Statistics Collaborative, Inc.)